Loading clinical trials...
Loading clinical trials...
Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to define th Maximum Tolerated Dose (MTD) and the recommended dose (RD) of ZD6474 in combination with a fixed standard dose of gemcitabine and capecitabine
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Sankt Gallen, Canton of St. Gallen, Switzerland
Research Site
Bellinzona, Switzerland
Start Date
July 1, 2006
Primary Completion Date
June 1, 2009
Completion Date
June 1, 2009
Last Updated
August 29, 2016
8
ACTUAL participants
Vandetanib
DRUG
Lead Sponsor
Sanofi
NCT05053971
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions